Lupin has received final approval for Calcipotriene Topical Solution, 0.005% (Scalp Solution), from USFDA.

The company has received approval to market a generic version of Dovonex Scalp Solution, 0.005% of Leo Pharmaceutical Products, from the United States Food and Drug Administration (USFDA).

Lupin’s Calcipotriene Topical Solution is suggested for the treatment of chronic, moderately severe psoriasis of the scalp.

Read EquityPandit’s Technical Analysis of Lupin Outlook for the Week